ClinicalTrials.gg
RecruitingNCT05267899Updated Sep 26, 2023

A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of WGI-0301 in Advanced Solid Tumors, sponsored by Zhejiang Haichang Biotech Co., Ltd.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Zhejiang Haichang Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how safe and tolerable the study drug is for patients with solid tumors.

The study is also done to learn how the study drug is taken up by your body; this is called Pharmacokinetic (PK) studies and how the study drug affects the body; this is called Pharmacodynamics (PD)

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Zhejiang Haichang Biotech Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Subjects must meet all the following criteria to participate this study

  1. Subject with based on 1.1.
  2. Advanced, or cytologically confirmed solid tumors who have progressed from current therapy or who have after prior therapy and are not candidates for potentially curative therapy.
  3. Pathologically confirmed solid tumors.
  4. Patients with advanced solid tumors (unresectable or ) who failed standard therapy (disease progression or intolerance).
  5. Capable of understanding the written , provides signed, dated, and witnessed written informed consent, and agrees to comply with the study protocol.
  6. Age 18 years or older at first screening/ examination visit.
  7. (ECOG) performance status of 0 to 2, measured within 72 hours of 1st treatment.
  8. Adequate hematological function [ (ANC) ≥ 1.5 × 109/L], [ ≥ 100 × 109/L], [ ≥ 9 g/dL], and [Serum albumin ≥ 2.8 g/dL].
  9. Adequate renal function [calculated estimate (eGFR) of ≥ 50mL/min] using the CKD-EPI Creatinine Equation (2021).
  10. Adequate hepatic function [total ≤ 1.5 x UNL; (aspartate transaminase) or ALT (alanine transaminase) ≤ 3 x UNL or ≤ 5 x UNL if due to liver involvement by tumor.
  11. Negative pregnancy test for women of (WOCBP) and males need to agree to use a highly effective method of if not surgically sterile prior to study entry, while on drug, and for 3 months' time after the last dose. Please refer to Appendix 1 for acceptable effective contraceptive methods.
  12. Subject who has predicted of at least 12 weeks.

Exclusion Criteria Subjects meet one or more of below criteria will be excluded

  1. Lactating, pregnant, or intend to be pregnant.
  2. Received anti-cancer therapy or other drugs within 4 weeks prior to the 1st dose of study drug.
  3. Patient in use of sensitive substrates of major cytochrome P450 enzymes and transporters based on FDA Drug Development and Drug Interactions, Table of Substrates, Inhibitors, and Inducers, or strong inducers of transporter, P-gp, including apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort. Patient in use of strong inhibitors of transporters based on based on FDA Drug Development and Drug Interactions, Table of Substrates, Inhibitors, and Inducers (Appendix 2).
  4. All acute toxic effect of any prior antitumor therapy resolved to Grade 1 before the start of study therapy (with the exception of alopecia [G 1 or 2 permitted], neurotoxicity [Grade ≤ 2 permitted], or selected lab parameters [Grade \< 2 permitted with exceptions noted below].
  5. Has evidence of another not in remission or history of such a malignancy within the last 3 years (except for treated basal or squamous cell carcinoma of the skin, or in situ cancer of the cervix). Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma; low grade prostate cancer treated with prostatectomy more than 5 years ago; early-stage melanoma treated with complete surgical excision more than 5 years ago; carcinoma in situ of cervix treated with cone procedure more than 8 years ago.
  6. Has symptomatic central nervous system (CNS) metastases, except where metastases are stable over a three-month period.
  7. Has unstable bleeding disorder or currently under non-established course of anticoagulant therapy (except for the use of heparinized saline to maintain the patency of central venous catheters).
  8. Has a medical history of symptomatic CHF ( [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.
  9. Has a medical history of myocardial infarction or unstable angina within 6 months before registration.
  10. Has a prolongation to > 470 ms based on a 12-lead in triplicate, or other abnormalities that in the opinion of the Investigator increase the risk of participating in the study.
  11. Has higher or equal to Grade 3 hypertension (≥ 160/100 mmHg) or ≤ 80/50 mmHg; has heart rate (HR) ≥ 100 beats per minute (bpm), or ≤ 45 bpm, confirmed by a repeat assessment.
  12. Has evidence of electrolyte imbalance such as hypokalemia, hypocalcemia, and hypomagnesaemia of Grade ≥ 2 (symptomatic, intervention indicated).
  13. Major surgery besides tumor resection, within 4 weeks prior to screening
  14. Has uncontrolled diabetes mellitus, neurologic or psychiatric condition, an ongoing systemic (including opportunistic) infections or any other significant or unstable concurrent medical illness that may increase the risk of study participants determined by Investigator.
  15. Has a known history of
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    WGI-0301

    Drug: WGI-0301

Interventions

  • WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Incidence and severity of treatment-related adverse events and serious adverse events

    Time frame: Approximately 16 months

  2. Recommended Phase 2 Dose of WGI-0301

    Based on dose-limiting toxicities, the maximal tolerated dose and all other available safety, pharmacokinetic/pharmacodynamic data as assessed by the cohort review committee

    Time frame: Approximately 16 months

Secondary outcomes

  1. Area under the curve

    Area under the plasma concentration time curve of WGI-0301

    Time frame: Approximately 16 months

  2. Maximum plasma concentration

    Highest observed plasma concentration of WGI-0301

    Time frame: Approximately 16 months

  3. Time of maximum plasma concentration

    Time to reach highest observed plasma concentration of WGI-0301

    Time frame: Approximately 16 months

  4. Half-life

    Plasma concentration half-life of WGI-0301

    Time frame: Approximately 16 months

07

Study locations

3 of 3 sites recruiting
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
    Recruiting
    • David Berz, MD, PhD, MPH · Contact
  • The Oncology Institute of Hope and Innovation
    Whittier, California 90603, United States
    Recruiting
    • Pamela Miel, MD · Contact562-693-4477
    • Pamela Miel, MD · Principal investigator
  • University of Maryland, Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
    Recruiting
    • Yixing Jiang, MD, PhD · Contactyjiang@umm.edu
    • Yixing Jiang, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Oct 2024, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Mar 7, 2022
StartActual
Aug 1, 2022
Primary completionEst.
Oct 15, 2024
CompletionEst.
Dec 31, 2024
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05267899
Lead sponsor
Zhejiang Haichang Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Mar 7, 2022
Start date
Aug 1, 2022
Primary completion
Oct 15, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 26, 2023

Study contacts

Chao Wang, Pharm. D, BCPS, CCRP
Contact
chao.wang@thewogroup.com
2407965552

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Akt-1 Antisense Oligonucleotide WGI-0301

Start the discussion